Infertility Drugs Market Report 2025 (Global Edition)

Global Infertility Drugs Market Report 2024 Market Size Split by Drug Class (Gonadotropins, Aromatase inhibitors, Selective estrogen receptor modulators Dopamine agonists, Other drug classes.), by Rou...

Infertility Drugs Market Report Description

We have various report editions of Infertility Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Infertility Drugs Market

To attract a growing number of clients, top infertility treatment providers are always concentrating on growing their product and service offerings. To obtain a competitive edge in the worldwide infertility treatment market, they have also implemented several strategies, including alliances, acquisitions, mergers, collaborations, the start of awareness campaigns and commercials, and the construction of new infertility treatment facilities and clinics. With a focus on digitalization, cryogenics, and reproductive genetics, the partnership will lead innovative initiatives to assist patients on their reproductive journeys, including those who need egg, sperm, or embryo donations. 

Top Companies Market Share in Infertility Drugs Industry: (In no particular order of Rank)

• Merck & Co.
• Inc.
• Ferring B.V.
• Organon Group of Companies
• Abbott
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Mankind Pharma
• Teva Pharmaceutical Industries LTD.
• Sano
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which region domintes the infertility drugs market?

The North American infertility drugs market accounted for xx% business share in 2024 and is anticipated to dominate during the forecast time frame the market will expand more quickly if more men and women embrace sedentary lifestyles. Infertility rates have increased nationwide in the USA as a result of the growing incidence of POCS patients in the country. PCOS affects 6% to 12% of women in the United States who are of reproductive age and is one of the most prevalent causes of infertility in women. This information comes from the Centers for Disease Control and Prevention (CDC). The need for infertility treatments will result from this for some time to come.
https://www.cdc.gov/reproductive-health/infertility-faq/index.html
 

Which region expanding at the fastest CAGR of infertility drugs market?

Asia Pacific is seeing an increase in infertility due to several causes. In nations like India, people are opting to put off marriage in favor of concentrating on their professions. Higher-educated individuals and those who married later tend to have primary infertility. Increased awareness of the availability of infertility treatment procedures, the growth of fertility centers in the region, rising healthcare costs, the rising rate of infertility in the area, and government initiatives to improve access to infertility treatment in developing countries are all contributing factors to the notable rise in medical tourism. 

The current report Scope analyzes Infertility Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

Infertility Drugs Market Analysis

Infertility Drugs Market Drug Type Segment Analysis

• Gonadotropins
• Aromatase inhibitors
• Selective estrogen receptor modulators Dopamine agonists
• Other drug classes

By drug class, the infertility drugs market is classified into gonadotropins, aromatase inhibitors, selective estrogen receptor modulators, dopamine agonists, and other drug classes. The gonadotropins segment accounted for xx% of the market share in 2024 and is projected to witness robust growth over the analysis timeframe. The sector share will be augmented by the rising demand for assisted reproductive technologies (ART), such as intrauterine insemination (IUI) and in-vitro fertilization (IVF), in which gonadotrophins are essential. Furthermore, new developments in science and technology are enabling the creation of gonadotrophin formulations that are more precise and focused.
•    For instance, according to an article published in Cell in May 2022, it was observed that male infertility is an increasing and serious medical concern that affects approximately half of infertile couples worldwide. 

(Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139678/)

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Infertility Drugs Industry. Request a Free Sample PDF!

Infertility Drugs Market Route of Administration Segment Analysis

• Parenteral
• Oral
• Topical

Based on the route of administration, the infertility drugs market is segmented into parenteral, oral, and topical. The parenteral route of administration is expected to register around USD xx billion by 2031. Injectables and intravenous infusions are examples of the parenteral approach, which provides quick and easy administration of infertility medications into circulation. This guarantees more effective and consistent medication absorption, which leads to a quicker beginning of action and better therapeutic results. Consequently, parenteral administration of infertility medications is becoming more and more popular among patients and healthcare professionals, driving market developments. Additionally, the parenteral method of administration enables customized treatment plans and accurate dosage, which increases market size.
•    For instance, In February 2024, Lupin, a major global pharma company, launched Ganirelix Acetate Injection. It is a single-dose prefilled syringe indicated for inhibiting premature luteinizing hormone (LH) surges in women who undergo ovarian hyperstimulation.

(Source:https://www.lupin.com/lupin-launches-ganirelix-acetate-injection-in-the-united-states/)

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Infertility Drugs Distribution Channel Segment Analysis

The distribution channel in the infertility drugs market is divided into hospital pharmacies, specialty & retail pharmacies, and online pharmacies. Hospital pharmacies accounted for USD xx billion in market revenue in 2024. The need for specialized pharmaceuticals will be fueled by increased healthcare awareness and the increasing frequency of infertility. Hospital pharmacies are well-positioned to address this need and guarantee their availability inside the hospital context, hence driving segment trends, thanks to their extensive selection of infertility medications. Hospital pharmacies are growing in this market because of their sophisticated pharmaceutical infrastructure and knowledge, which includes compounding capabilities that enable individualized and customized therapies.
•    For instance, according to the Centers for Drug Control and Prevention (CDC), around 489 clinics in the U.S. offer infertility-related treatment services such as consultations and assisted reproductive technology (ART).

(Source:https://www.cdc.gov/art/reports/2021/pdf/Report-ART-Fertility-Clinic-National-Summary-H.pdf)

• Hospital Pharmacy
• Specialty & Retail Pharmacy
• Online Pharmac

Infertility Drugs End-user Segment Analysis

By gender, the infertility drugs market is segmented into female and male. The female segment accounted for significant market revenue in 2024 and is expected to grow at xx% during the forecast period. The increase in female infertility cases is one of the main factors propelling the market. Moreover, around 1 in 4 (26%) of the women in this category experience reduced fecundity, which is the inability to become pregnant or carry a pregnancy to term. As a result, segmental expansion will be accelerated by rising female infertility. Furthermore, it is projected that the growing number of women with Polycystic Ovary Syndrome (PCOS) would contribute to the segment's growth.

(Source:https://www.cwcare.net/national-infertility-awareness-week-april-23-april-29/#:~:text=Among%20heterosexual%20women%20aged%2015,(known%20as%20impaired%20fecundity.)

•    For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., among married women aged 15 to 49 years with no prior births, about 1 in 5 (19%) are unable to get pregnant after one year of infertility.

(Source:https://www.cdc.gov/reproductive-health/women-health/index.html#:~:text=a%20prevalent%20practice.-,Infertility,after%201%20year%20of%20trying.)

•    For instance, according to the U.S. Department of Health and Human Services, about 11% of women are affected by infertility at reproductive age compared to 9% of men in the U.S.

(Source:https://www.nichd.nih.gov/health/topics/infertility/conditioninfo/common#:~:text=About%209%25%20of%20men%20and,States%20have%20experienced%20fertility%20problems.&text=In%20one%2Dthird%20of%20infertile,both%20the%20man%20and%20woman.)

• Men
• Women

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion